SciClone Pharmaceuticals, Inc. announced that it anticipates 2014 sales revenue of $130 million to $135 million, representing an approximate 30% increase of its core business revenue (the core business revenue excludes all Sanofi products and certain Pfizer products, including Adriamycin and Daunoblastina).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.72 HKD | +0.86% | 0.00% | +34.48% |
26/06 | SciClone Pharmaceuticals Limited Announces Retirement of Wang Haixia as Non-Executive Director | CI |
21/06 | SciClone Pharmaceuticals Limited(SEHK:6600) dropped from S&P Global BMI Index | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+34.48% | 145.57Cr | |
+2.99% | 9.52TCr | |
-4.34% | 3.75TCr | |
-10.41% | 3.38TCr | |
+75.79% | 2.82TCr | |
-14.61% | 1.56TCr | |
-3.46% | 1.36TCr | |
-12.31% | 1.15TCr | |
+184.77% | 1.08TCr | |
-54.13% | 923.34Cr |
- Stock Market
- Equities
- 6600 Stock
- News SciClone Pharmaceuticals (Holdings) Limited
- SciClone Pharmaceuticals, Inc. Provides Sales Revenue Guidance for 2014